UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
Keryx Biopharmaceuticals, Inc.
Common Stock, par value $.001 per share
(Title of Class of Securities)
May 28, 2003
(CUSIP Number: 492515101)
Date of event which requires filing
May 15, 2003
Check the appropriate box to designate the rule pursuant to which the schedule
is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be filled for the purpose of Section 18 of the Securities Exchange Act of
1934 (the "Act") or otherwise subject to the liabilities of that section of the
Act, but shall be subject to all other provisions of the Act (however, see the
Notes to Schedule 13G).
1
------------------------------- ------------------------------
CUSIP No. 492515101 13G
-------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Jay Lobell
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
-------------------------------------------------------------------------------
5 SOLE VOTING POWER
2,374,187
NUMBER OF
SHARES ------------------------------
BENEFICIALLY
OWNED BY 6 SHARED VOTING POWER
EACH 0
REPORTING ------------------------------
PERSON
WITH
7 SOLE DISPOSITIVE POWER
2,374,187
------------------------------
8 SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,374,187
-------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES*
-------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.6%
-------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
(IN)
-------------------------------------------------------------------------------
2
ITEM 1(a). NAME OF ISSUER:
Keryx Biopharmaceuticals, Inc. (the "Company")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
750 Lexington Avenue
New York, NY 10022
(212) 531-5965
ITEM 2(a) NAME OF PERSON FILING:
Jay Lobell
ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
365 West End Ave. NY, NY 10024
ITEM 2(c). CITIZENSHIP:
United States
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, $0.001 par value.
ITEM 2(e). CUSIP NUMBER:
492515101
ITEM 3. If this statement is filed pursuant toss.ss.240.13d-1(b) or 240.13d-2(b) or (c),
check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) [ ] Investment [company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C
80a-8).
(e) [ ] An investment]adviser in accordance with
ss.240.13d-1(b)(1)(ii)(E);
(f) An employee ] benefit plan or endowment fund in accordance with
ss.240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance
with ss. 240.13d-1(b)(1)(ii)(G);
3
(h) [ ] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church) plan] that is excluded from the definition of an
investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, (in accordance with ss.240.13d-1(b)(1)(ii)(J).
(h) [ ] Not Applicable
ITEM 4. OWNERSHIP
The Reporting Person may be deemed to beneficially own 2,374,187
(11.6%) shares of Common Stock of the Issuer. Beneficial
ownership consists of voting and dispositive power over (i)
1,374,187shares owned by a trust for which Mr. Lobell is the
distribution and investment advisor, and (ii) 1,000,000 shares
owned by the Rosenwald 2000 Family Trust, for which Mr. Lobell
serves as the trustee.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
See Item 4 above.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
Not applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in a transaction having that purpose and effect.
4
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: May 28, 2003 /s/ Mr. Jay Lobell
New York, NY ---------------------
Mr. Jay Lobell
5